Document:

Sponsored Research and Vaccine Production Agreement

 EXHIBIT 10.49 
 TEXT MARKED BY [ * * *] HAS BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT 

AND WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. 
 SPONSORED
RESEARCH AND VACCINE PRODUCTION AGREEMENT 
 [GMP MANUFACTURING OF ICT-107 DENDRITIC CELL-BASED 

VACCINE FOR GLIOBLASTOMA] 
 This Sponsored Research and Vaccine Production Agreement (“Agreement”) is made by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation
(“Institution”), with offices located at 3160 Chestnut Street, Suite 200, Philadelphia, PA, Philadelphia, PA 19104-6205, and ImmunoCellular Therapeutics, Ltd., a corporation organized and existing under the laws of California
(“Sponsor”), having a place of business at 21900 Burbank Blvd., 3rd Floor, Woodland Hills, CA 91367. 
 This Agreement is effective as of the 1st day of January, 2011 (“Effective Date”). 
 RECITALS 

WHEREAS, the parties entered into a Sponsored Research Agreement (“SRA”), having an effective date of 04/1/2010 and a total
budget of $[***], to support research, process development, and validation work for the production of Sponsor’s ICT-107 dendritic cell based vaccine for the treatment of glioblastoma; and 

WHEREAS, the parties executed Amendment No. 1 of the SRA (“Amendment”), having an effective date of 09/29/2010, to extend
the term of the SRA by three (3) months at [***]; and 
 WHEREAS, the parties entered into an exclusive option
agreement (“Option Agreement”), having an effective date of 03/01/2010 and a term of twelve (12) months, to permit Sponsor to conduct due diligence analysis of certain Institution Background Intellectual Property (as defined below)
relating to the production and cryopreservation of dendritic cell vaccines with the intent of entering into license negotiations with Institution for certain Institution Background Intellectual Property; and 

WHEREAS, the parties wish to extend their existing relationship(s) to further support research, process development, validation work, and
the GMP production of ICT-107 dendritic cell vaccines for use in Sponsor’s IND-supported Phase II clinical trials; and 

WHEREAS, the Sponsored Research (as defined below) contemplated by this Agreement is currently available on a limited basis from
Institution, is of mutual interest and benefit to Institution and to the Sponsor, and will further Institution’s public mission as an academic institution in a manner consistent with its status as a non-profit, tax-exempt corporation;

 WHEREAS, in furtherance of Sponsor’s exploitation of the rights granted pursuant to the Sponsored Research Agreement,
the Amendment, and the Option Agreement, Sponsor desires to have Institution produce, and Institution desires to produce and supply certain dendritic cell vaccines for Sponsor in accordance with the terms and conditions of this Agreement;

 NOW, THEREFORE, In consideration of the promises and mutual covenants contained herein, and
intending to be legally bound hereby, the parties hereto agree as follows: 
 1. DEFINITIONS 

1.1 “Background Intellectual Property” means any information, data, material, inventions, processes, protocols,
methods, techniques, technologies, software, patents, or other items patentable or otherwise that are (i) owned or controlled by Institution prior to the Effective Date and (ii) made available by or on behalf of Institution hereunder
solely for the conduct of the Sponsored Research, excluding Institution Materials. 
 1.2 “Field” means
process development and GMP production of ICT-107 for use as a dendritic cell-based vaccine for glioblastoma. 

1.3 “Institution Inventions” means all inventions or discoveries, whether or not patentable, conceived and/or
reduced to practice solely by employees of Institution that arise during the Term of the Sponsored Research. 

1.4 “Institution Materials” means standard operating procedures and forms of the Clinical Cell and Vaccine
Production Facility (CVPF) of the Institution, including all parts, unmodified derivatives and unmodified progeny thereof, and related information disclosed by Institution being provided to Sponsor for the performance of the Sponsored Research in
the Field during the Term. 
 1.5 “Joint Inventions” means all inventions or discoveries, whether or
not patentable, conceived and/or reduced to practice jointly by employees and/or agents of Institution and by employees and/or agents of Sponsor that arise during the Term of the Sponsored Research. 

1.6 “Principal Investigator” means Dr. Bruce Levine who has agreed to serve as faculty investigator for the
Sponsored Research and shall be responsible for the conduct, supervision and administration of the Sponsored Research. 
 1.7 “Project Materials” means ICT-107 dendritic cell vaccines produced by the CVPF during the Term of the Sponsored Research. 

1.8 “Research Results” means all data and information which are generated in the performance of the Sponsored
Research during the Term of this Agreement. Research Results expressly excludes Background Intellectual Property, Institution Inventions, Institution Materials, Joint Inventions, and Sponsor Inventions. 

1.9 “Sponsor Information” means all information, data, material and other items that are supplied to Institution
by or on behalf of Sponsor for the purposes of conducting the Sponsored Research, excluding Research Results. 

1.10 “Sponsor Inventions” means all inventions or discoveries, whether or not patentable, conceived and/or
reduced to practice solely by employees of Sponsor relating to ICT-107 that arise during the Term of the Sponsored Research. 

  
 2 

 1.11 “Sponsor Option” is defined in Section 7.4. 

1.12 “Sponsored Research” means the research program and GMP production of the ICT-107 dendritic cell vaccine as
described in Attachment A to this Agreement. 
 1.13 “Term” is defined in Section 3.1. 

2. SPONSORED RESEARCH 
 2.1 Institution shall commence the Sponsored Research after the Effective Date of this Agreement and upon payment by Sponsor of any funds owed, and shall use good faith efforts to conduct such Sponsored
Research substantially in accordance with the terms and conditions of this Agreement. Sponsor acknowledges that Institution and the Principal Investigator shall have the freedom to conduct and supervise the Sponsored Research in a manner consistent
with Institution’s educational and research missions. 
 2.2 If the services of the Principal Investigator
become unavailable to Institution for any reason, Institution shall be entitled to designate another member of its faculty who is acceptable to Sponsor to serve as the Principal Investigator of the Sponsored Research. If a substitute Principal
Investigator has not been designated within sixty (60) days after the original Principal Investigator ceases his or her services under this Agreement, either party may terminate this Agreement upon written notice thereof to the other party,
subject to the provisions of Article 9. 
 2.3 Institution shall manufacture the Project Materials in compliance
with all GMP practices and regulations. Institution shall deliver the Project Materials within the timeframes set forth in Attachment A. 
 3. TERM OF AGREEMENT 
 3.1 The Term of this Agreement shall begin
on the Effective Date of this Agreement and shall end one (1) year following the Effective Date unless terminated sooner pursuant to Sections 2.2 or 9.1 hereof. This Agreement may be extended or renewed only by mutual written agreement executed
by duly authorized representatives of the parties. 
 4. REIMBURSEMENT OF COSTS, PAYMENT 

4.1 Sponsor shall reimburse Institution for an amount equal to its expenditures and reasonable overhead incurred in the
conduct of the Sponsored Research in an amount not to exceed the total amount of $[***] as set forth in Attachment A. Sponsor acknowledges that this amount is a good faith estimate only and not a guarantee of the cost to conduct the Sponsored
Research. If at any time Institution determines that it will require additional funds for the Sponsored Research due to a change in the scope of the Sponsored Research, it shall notify Sponsor and provide an estimate of the additional amount.
Sponsor shall not be liable for any costs in excess of the amount of $[***] unless it has agreed in writing to provide additional funds. 

  
 3 

 4.2 Sponsor shall make payments in advance to Institution in accordance with
the payment schedule set forth in Attachment A. All payments shall clearly identify the Principal Investigator and Sponsored Research. All payments are to be made by check payable in United States dollars, to “The Trustees of the University of
Pennsylvania”, and sent to: 
 Office of Research Services 
 University of Pennsylvania 
 P-221 Franklin Building 

3451 Walnut Street 
 Philadelphia, PA 19104-6205

 Attention: Executive Director 

23-1352685 
 Institution Tax Identification
Number 
 4.3 Title to any equipment, laboratory animals, or any other materials made or acquired with funds
provided under this Agreement shall vest in Institution (excluding Project Materials and ICT-107 formulations), and such equipment, animals, or materials shall remain the property of Institution following termination of this Agreement. 

5. RECORDS AND REPORTS 
 5.1 Each party shall keep the other party reasonably informed of the progress of its obligations under the Sponsored Research by written reports on a regular basis in accordance with a schedule agreed to
by the parties but not more frequently than once per month following the Effective Date. Principal Investigator shall maintain records of the results of the Sponsored Research and shall provide Sponsor with reports of the progress, results of the
Sponsored Research, and the deliverables outlined in Attachment A. Institution shall maintain records of the use of the funds provided by Sponsor and shall make such records available to Sponsor upon reasonable notice during Institution’s
normal business hours, but not more frequently than once per six (6) month period following the Effective Date. 
 6.
RESEARCH RESULTS, REPORTS, OWNERSHIP OF INFORMATION, SPONSOR REPORTS 
 6.1 Sponsor shall have the right to use
Research Results disclosed to Sponsor in records and reports and the Project Materials for any reasonable purpose, including regulatory submissions and the conduct of clinical trials. Institution shall be entitled to use the Research Results solely
for its own academic research purposes, patenting, and publication as provided under Section 8. Research Results will be owned jointly by the parties. Principal Investigator shall not disclose Sponsor Confidential Information, or Sponsor
Confidential Information contained within the deliverables whether generated by Institution or by Sponsor, to any party outside of the Institution without the prior written consent of Sponsor, except for patenting and publication as provided under
Section 8. 
 6.2 Institution and the Principal Investigator hereby grant Sponsor a royalty-free,
nontransferable, non-exclusive right to copy, reproduce and distribute any research reports 

  
 4 

 
furnished to Sponsor under this Agreement. Sponsor may not charge fees for said research reports, use said research reports for advertising or promotional activities, or alter or modify said
research reports without the prior written permission of Institution. 
 6.3 Ownership of all right, title and
interest in and to Sponsor Information and Project Materials shall reside solely with Sponsor. Ownership of all right, title and interest in and to Background Intellectual Property and Institution Materials shall reside with Institution. Except as
specifically set forth in this Agreement, neither party shall acquire any license or other intellectual property interest, by implication or otherwise, in any information, know-how or materials disclosed to it under this Agreement or under any
patents or patent applications owned or controlled by the other party. Background Intellectual Property and Institution Materials are considered proprietary to Institution. Sponsor shall not distribute or release the Background Intellectual Property
or Institution Materials to any person who is not a Sponsor’s employee. Sponsor shall ensure that no one will be allowed to take or send the Background Intellectual Property or Institution Materials to any location other than Sponsor’s
facility, unless prior written permission is obtained from the Principal Investigator at Institution. 
 6.4
Sponsor shall promptly report to Institution any findings from monitoring or safety reporting of this Sponsored Research or studies using the Research Results or Project Materials that could influence the conduct of the research or alter the
IRB’s approval to continue the Sponsored Research. 
 7. INTELLECTUAL PROPERTY 

7.1 It is recognized that the existing and/or previously (prior to the Effective Date) conceived inventions, discoveries
and technologies of Sponsor and Institution are their separate property and are not affected by this Agreement. Institution shall promptly inform Sponsor in writing of the development, making, conception or reduction to practice of any Institution
Inventions and any Joint Inventions and Sponsor shall promptly inform Institution in writing of the development, making, conception or reduction to practice of any Sponsor Inventions and any Joint Inventions. Inventorship of Institution Inventions,
Joint Inventions, and Sponsor Inventions shall be determined in accordance with United States patent law. Ownership shall follow inventorship. Subject to the rights granted to the parties under Section 7.4, each party shall have the right to
use, sell, keep, license or assign its interest in Joint Inventions without the consent of and without accounting to the other party. 
 7.2 Principal Investigator shall provide Institution and Sponsor a written disclosure of any Institution Inventions and Joint Inventions reasonably considered patentable. Sponsor shall advise Institution
in writing, no later than thirty (30) days after receipt of such disclosure, whether it requests Institution to file and prosecute patent applications related to such Institution Inventions and/or Joint Inventions. If Sponsor does not request
Institution to file and prosecute such patent applications, Institution may proceed with such preparation and prosecution at its own cost and expense; but such patent applications shall be excluded from Sponsor’s option under Section 7.5
hereof. Sponsor shall provide Institution with a written disclosure of any Joint Inventions and Sponsor Inventions. 

  
 5 

 7.3 Institution shall control the preparation and prosecution of all patent
applications and the maintenance of all patents related to Institution Inventions and Joint Inventions. With regard to any patent applications filed at the request and expense of Sponsor, Institution will consult with Sponsor on patent prosecution.
Sponsor shall reimburse Institution upon receipt of invoice for all documented expenses incurred in connection with the filing and prosecution of the patent applications and maintenance of the patents that Sponsor has requested Institution to
prosecute under Section 7.2 hereof. 
 7.4 In consideration of Sponsor’s funding of the Sponsored
Research and payment for intellectual property expenses as provided for in Section 7.3, Institution grants Sponsor an exclusive option (the “Sponsor Option”) to negotiate to acquire an exclusive, worldwide, sublicensable license in
the Field to practice under the Background Intellectual Property, Institution Inventions, and Institution’s ownership interest in the Joint Inventions on commercially reasonable terms to be negotiated in good faith by the parties. If Sponsor
and Institution fail to execute a license agreement within six (6) months after disclosure of the Background Intellectual Property, Institution Inventions, and/or Joint Inventions to Sponsor, or if Sponsor fails to make payment for intellectual
property expenses as provided for in Section 7.3, Institution shall be free to license the Background Intellectual Property, Institution Inventions and Institution’s ownership interest in the Joint Inventions to any party upon such terms
as Institution deems appropriate, without any further obligation to Sponsor. 
 7.5 Any license granted to
Sponsor pursuant to Section 7.4 hereof shall be subject to Institution’s right to use and permit other non-profit organizations to use Background Intellectual Property, Institution Inventions and Joint Inventions for educational and
research purposes and, if applicable, to the rights of the United States government reserved under Public Laws 96-517, 97-256 and 98-620, codified at 35 U.S.C. 200-212, and any regulations issued thereunder. 

8. CONFIDENTIALITY, PUBLICATION, USE OF NAME 
 8.1 Institution shall not be obligated to accept any confidential information from Sponsor. If Sponsor desires to furnish any confidential information to the Principal Investigator, Sponsor may request
the Principal Investigator to sign the “Agreement between Sponsor and Principal Investigator concerning Sponsor’s Confidential Information” that is attached as Attachment B. Institution bears no responsibility for maintaining the
confidentiality of any confidential information of Sponsor provided under such an individual agreement. 
 8.2 In
order to preserve the patentability of Background Intellectual Property, Institution Inventions, Institution Materials, and Joint Inventions, Sponsor shall maintain Background Intellectual Property, Institution Inventions, Institution Materials and
Joint Inventions and information provided pursuant to the Sponsored Research (whether oral or written) as confidential and shall not disclose such information to any third party until the publication of such information by the Principal Investigator
or until Institution provides Sponsor with written verification that all desirable patentable inventions have been protected, whichever occurs sooner. The limitations set forth in this Section 8.2 shall not apply to any Research Results that
Sponsor provides to any regulatory authority in connection with the clinical testing or commercialization of any ICT-107 based product. 

  
 6 

 8.3 Institution shall be free to publish, present or otherwise disclose
Research Results or other information and material resulting from the Sponsored Research for any purpose, except that Institution shall not publish or otherwise publicly disclose any Sponsor Confidential Information or any Sponsor Confidential
Information contained within the deliverables that will or have been filed by Sponsor on a confidential basis with any regulatory authority in connection with the clinical testing or commercialization of any ICT-107 based product. Institution shall
furnish the Sponsor with a copy of any proposed disclosure, publication or presentation at least thirty (30) days in advance of the submission of said proposed disclosure, in order for Sponsor to review and comment on said proposed disclosure.

 8.4 Institution shall not use Sponsor’s name without Sponsor’s prior written consent except that
Institution may acknowledge Sponsor’s funding of this Sponsored Research and any scientific contributions in scientific publications and in listings of sponsored research projects. Sponsor shall not use Institution’s name, mark or symbol,
or the name of any trustee, officer, faculty member, student or employee thereof, without Institution’s prior written consent, provided, that Sponsor may disclose or file a copy of this Agreement with any applicable securities regulatory agency
or securities exchange if Sponsor’s counsel determines that such filing or disclosure is required. 
 8.5
Institution shall not manufacture for research and development or commercial purposes for itself or any third party during or at any time after the term of this Agreement any vaccine that is identical or substantially identical to ICT-107.

 9. TERMINATION 
 9.1 In addition to the termination right set forth in Section 2.2 hereof, either party may terminate this Agreement effective upon written notice to the other party, if the other party breaches any
of the terms or conditions of this Agreement and fails to cure such breach within thirty (30) days after receiving written notice thereof. In the event of an incurable breach, the non-breaching party may terminate this Agreement effective
immediately upon written notice to the breaching party. 
 9.2 In the event of termination of this Agreement
prior to its stated term whether for breach or for any other reason whatsoever, Institution shall be entitled to retain from the payments made by Sponsor prior to termination Institution’s reasonable costs of concluding the work in progress,
and Institution shall deliver to Sponsor all Project Materials produced through the date of termination. Allowable costs include, without limitation, all costs or noncancellable commitments incurred prior to the receipt, or issuance, by Institution
of the notice of termination, and the full cost of each employee, student and faculty member supported hereunder through the end of such commitments. In the event of termination, Institution shall submit a final report of all costs incurred and all
funds received under this Agreement within ninety (90) days after the effective termination date. The report shall be accompanied by a check in the amount of any excess of funds advanced over costs and allowable commitments incurred. In case of
a deficit of funds, Sponsor shall pay Institution the amount needed to cover costs and allowable commitments incurred by Institution under this Agreement. 

  
 7 

 9.3 Termination of this Agreement shall not affect the rights and
obligations of the parties accrued prior to termination hereof. The provisions of Article 4, entitled Reimbursement of Costs, Payment; Article 6, entitled Sponsor’s Rights in Research Results, Reports, Ownership of Information; Article 7,
entitled Intellectual Property; Article 8 entitled Confidentiality, Publication, Use of Name; Article 10, entitled Disclaimer of Warranties, Indemnification, Insurance; and Article 11, entitled Additional Provisions, shall survive such termination.

 10. DISCLAIMER OF WARRANTIES, INDEMNIFICATION, INSURANCE 

10.1 INSTITUTION MAKES NO WARRANTIES, EXPRESS OR IMPLIED, AS TO ANY MATTER WHATSOEVER, INCLUDING, WITHOUT LIMITATION,
WARRANTIES WITH RESPECT TO THE CONDUCT, COMPLETION, SUCCESS OR PARTICULAR RESULTS OF THE SPONSORED RESEARCH, OR THE CONDITION, OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE SPONSORED RESEARCH OR ANY BACKGROUND INTELLECTUAL
PROPERTY, INSTITUTION INVENTIONS, JOINT INVENTIONS, INSTITUTION MATERIALS, PROJECT MATERIALS OR RESEARCH RESULTS OR THAT USE OF THE BACKGROUND INTELLECTUAL PROPERTY, INSTITUTION INVENTIONS, JOINT INVENTIONS, INSTITUTION MATERIALS, PROJECT MATERIALS
OR RESEARCH RESULTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER INTELLECTUAL PROPERTY RIGHT OF A THIRD PARTY. INSTITUTION SHALL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, PUNITIVE OR OTHER DAMAGES SUFFERED BY SPONSOR OR
ANY OTHER PERSON RESULTING FROM THE SPONSORED RESEARCH OR THE USE OF ANY BACKGROUND INTELLECTUAL PROPERTY RIGHTS, INSTITUTION INVENTIONS, JOINT INVENTIONS, INSTITUTION MATERIALS, PROJECT MATERIALS, RESEARCH RESULTS OR ANY PRODUCTS RESULTING
THEREFROM. 
 10.2 Sponsor shall defend, indemnify and hold harmless Institution, the Principal Investigator and
any of Institution’s faculty, students, representative and employees, trustees, officers, affiliates and agents (hereinafter referred to collectively as the “Indemnified Persons”) from and against any and all liability, claims,
lawsuits, losses, damages, costs or expenses (including, without limitation attorneys’ fees for personal injury (including death) or economic loss arising out of or connected with performance of the Sponsored Research or clinical trials
performed using materials produced for Sponsor under this Agreement, including the use by Sponsor or Sponsor’s clinical sites of Research Results and/or Project Materials), which the Indemnified Persons may hereafter incur, or be required to
pay as a result of Sponsor’s or Sponsor’s clinical sites use of the results of Sponsored Research or any Background Intellectual Property, Institution Inventions, Institution Materials, Joint Inventions, Project Materials or Research
Results or as a result of any breach of this Agreement or any act or omission of Sponsor, its employees, affiliates, contractors, licensees or agents. Institution shall notify Sponsor upon learning of the institution or threatened institution of any
such liability, claims, lawsuits, losses, damages, costs and expenses and Institution shall cooperate with Sponsor in every proper way in the defense or settlement thereof at Sponsor’s request and expense. Sponsor shall not dispose or settle
any claim admitting liability on the part of the Institution without Institution’s prior written consent. 

  
 8 

 10.3 INSURANCE. Sponsor shall maintain during the performance of this
Agreement a policy or policies of comprehensive general liability insurance at levels sufficient to support the indemnification obligations in this Agreement. This includes broad form and contractual liability and product liability, in a minimum
amount of $3,000,000 combined single limit per occurrence and in the aggregate with respect to personal injury, bodily injury and property damage. Sponsor will provide Institution with a certificate of insurance evidencing such coverage at the
request of Institution. 
 11. ADDITIONAL PROVISIONS 

11.1 No rights hereunder may be assigned by either party, directly or by merger or other operation of law, without the
express written consent of the other party. Any prohibited assignment of this Agreement or the rights hereunder shall be null and void. No assignment shall relieve a party of responsibility for the performance of any accrued obligations, which it
has prior to such assignment. 
 11.2 A waiver by either party of a breach or violation of any provision of this
Agreement will not constitute or be construed as a waiver of any subsequent breach or violation of that provision or as a waiver of any breach or violation of any other provision of this Agreement. 

11.3 Nothing herein shall be deemed to establish a relationship of principal and agent between Institution and Sponsor,
nor any of their agents or employees, nor shall this Agreement be construed as creating any form of legal association or arrangement which would impose liability upon one party for the act or failure to act of the other party. Nothing in this
Agreement, express or implied, is intended to confer on any person other than the parties hereto or their permitted assigns, any benefits, rights or remedies. 
 11.4 Notices, statements, reports and other communications under this Agreement shall be in writing and shall be deemed to have been received as of the date dispatched if sent by public overnight courier
(e.g., Federal Express) and addressed as follows: 
 If to Institution: 
 Office of Research Services 
 University of Pennsylvania 

P221 Franklin Building 
 3451 Walnut Street 
 Philadelphia, PA 19104-6205 

Attn.: Executive Director 
 Center for Technology Transfer 
 University of Pennsylvania 

3160 Chestnut Street, Suite 200 
 Philadelphia, PA 19104 
 Attn: Executive Director 

  
 9 

 If to Principal Investigator: 
 Bruce Levine, PhD 
 M6.40 Maloney 

3400 Spruce Street 
 Philadelphia, PA 19104 
 If to Sponsor: 

ImmunoCellular Therapeutics, Ltd. 
 21900 Burbank Blvd., 3rd Floor 
 Woodland Hills, CA 91367 

(818) 992-2907 

ATTN: CEO 
 11.5 This Agreement shall be construed and governed in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to conflict of law provisions. The parties hereby submit to the
exclusive jurisdiction of and venue in any state or federal courts located within the Eastern District of Pennsylvania with respect to any and all disputes concerning the subject of this Agreement. The parties agree that the provisions of this
Agreement are intended to be interpreted and implemented so as to comply with all federal, state and local laws, rules and regulations applicable to the Institution, including, without limitation, Internal Revenue Service requirements regarding the
avoidance of unrelated business income and appropriate use of the proceeds of tax exempt bonds. If it is determined by the Internal Revenue Service or any other federal, state or local agency, department or instrumentality that the provisions of
this Agreement are not in compliance with laws, rules and regulations applicable to Institution or that performance by Institution under this Agreement would not be in compliance with such, then the parties agree to modify the provision and the
implementation of this Agreement so as to be in compliance with all applicable federal, state and local laws, rules and regulations as determined by such governmental body. 

11.6 Institution and Sponsor shall not discriminate against any employee or applicant for employment because of race,
color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or because he or she is a disabled veteran or veteran of the Vietnam Era. 

11.7 Neither party shall be liable for any failure to perform as required by this Agreement to the extent such failure to
perform is due to circumstances reasonably beyond such party’s control, including, without limitation, labor disturbances or labor disputes of any kind, accidents, failure of any governmental approval required for full performance, civil
disorders or commotions, terrorism, acts of aggression, acts of God, energy or other conservation measures imposed by law or regulation, explosions, failure of utilities, mechanical breakdowns, material shortages, disease, or other such occurrences.

 11.8 Sponsor shall comply with all laws, regulations and other legal requirements applicable to Sponsor in
connection with this Agreement, including but not limited to any legal requirements applicable to Sponsor’s use of the results of the Sponsored Research or 

  
 10 

 
any Background Intellectual Property, Institution Inventions, Institution Materials, Joint Inventions or Research Results and laws controlling the export of technical data, computer software,
laboratory prototypes, and all other export controlled commodities. 
 11.9 This Agreement inclusive of its
Attachments embodies the entire understanding between the parties relating to the subject matter hereof and supersedes all prior understandings and agreements, whether written or oral. This Agreement may not be varied except by a written document
signed by duly authorized representatives of both parties. 
 IN WITNESS WHEREOF, the duly authorized representatives of the
parties hereby execute this Agreement as of the date first written above. 
  

									
	The Trustees of the University of Pennsylvania	 		 	ImmunoCellular Therapeutics, Ltd.
					
	By:	 	/s/ John Swartley	 		 	By:	 	/s/ Manish Singh
	Name:	 	John Swartley, Ph.D.	 		 	Name:	 	Manish Singh, Ph.D.
	Title:	 	Deputy Executive Director	 		 	Title:	 	President & CEO
		 	Center for Technology Transfer	 		 		 	
					
	Date:	 	December 21, 2010	 		 	Date:	 	Jan 3, 2011
				
	I have read and agreed to the responsibilities of the Principal Investigator:	 		 		 	
					
	By:	 	/s/ Bruce Levine	 		 		 	
					
	Date:	 	December 23, 2010	 		 		 	

  
 11 

 Attachment A 
 Summary of Sponsored Research 
 [***] 

  
 12 

 Attachment B 
 Sponsor Confidential Information 
 The free publication and dissemination of
research results and information is an essential and long-standing policy of the University of Pennsylvania (“Institution”). Because of the negative impact confidentiality obligations can have on the educational mission of the Institution
and the free communication of research results, the Institution does not undertake to keep proprietary information provided by a commercial sponsor confidential. Under certain circumstances, however, the Institution recognizes that an Institution
principal investigator (the “Principal Investigator”) under a commercially sponsored research program may desire to receive confidential and proprietary information of the commercial sponsor (“Sponsor”) that the Principal
Investigator considers essential for the conduct of the research program. Accordingly, the Institution will permit the Principal Investigator to accept confidential information of a Sponsor under the terms and conditions of the agreement between the
Sponsor and Principal Investigator stated below. 
 Agreement between Sponsor and Principal Investigator 

Concerning Sponsor Confidential Information 
 In connection with research to be conducted at the Institution sponsored by ImmunoCellular Therapeutics, Ltd.,(“Sponsor”) and relating to process development work and validation work for ICT-107
(the “Sponsored Research”), Sponsor desires to provide Dr. Bruce Levine (“Principal Investigator”) with certain information that Sponsor considers confidential. 

 

	 	1.	For purposes of this Agreement, “Confidential Information” means only confidential information of Sponsor related to the Sponsored Research that is disclosed
to the Principal Investigator by Sponsor in writing and conspicuously marked as confidential and proprietary at the time of disclosure, or, if disclosed visually or orally, is stated to be confidential and proprietary at the time of disclosure and
confirmed by a written summary describing the information in reasonable detail delivered by Sponsor to Principal Investigator within seven (7) days after disclosure. Notwithstanding anything to the contrary contained in this Agreement or the
markings on any document disclosed by Sponsor, Confidential Information does not include: 

  

	 	(a)	subject to the limitations set forth in Section 8.3 of the Sponsored Research Agreement between Sponsor and Institution, information that is reasonably required by
scientific standards for publication of the Sponsored Research, or any information that is necessary for other scholars to verify the results of the Sponsored Research; 

 

	 	(b)	information that is in the public domain at the time Sponsor discloses it to Principal Investigator or that thereafter enters the public domain through no fault of
Principal Investigator; 

  
 13 

	 	(c)	information that was known to Principal Investigator or to the Institution before the date Sponsor discloses it to Principal Investigator, or that becomes known to
Principal Investigator or the Institution through a third party having an apparent bona fide right to disclose the information; 

  

	 	(d)	information that is independently developed by Institution personnel; 

  

	 	(e)	information that is disclosed by Principal Investigator or the Institution in accordance with the terms of Sponsor’s written approval; 

 

	 	(f)	information that is required to be disclosed for compliance with any Federal, state or local law or regulation, or required to be disclosed by a court of law or
governmental authority, provided that the disclosing party provides Sponsor reasonable prior written notice of such disclosure. 

  

	 	2.	The Principal Investigator retains the right to refuse to accept any Confidential Information that the Principal Investigator does not consider to be essential to the
performance of the Sponsored Research or that the Principal Investigator believes to be improperly designated as Confidential Information. 

  

	 	3.	In the event the Principal Investigator does accept any Confidential Information, for a period of five (5) years after Principal Investigator’s acceptance of
Confidential Information, Principal Investigator agrees to use efforts no less than those Principal Investigator employs with respect to Principal Investigator’s own confidential information: 

 

	 	(a)	not to disclose the Confidential Information to third parties without Sponsor’s consent to such disclosure; and 

 

	 	(b)	to use the Confidential Information only in furtherance of the Sponsored Research. 

 

	 	4.	Sponsor specifically acknowledges its understanding that the Principal Investigator’s efforts hereunder will not necessarily conform to prevailing commercial
standards for the protection of confidential and proprietary information. Sponsor expressly agrees that the Institution shall not be liable for any disclosure of Sponsor’s Confidential Information. 

  
 14 

	 	5.	This Agreement sets forth the entire understanding of Sponsor and Principal Investigator with respect to the subject matter hereof, supersedes any prior agreement
between Sponsor and Principal Investigator, and there are no other understandings or agreements, written or oral, between them relating to such subject matter. The Agreement may not be changed or supplemented in any way except by a written agreement
duly executed by both Sponsor and Principal Investigator and approved by the Institution. This Agreement shall be governed by, enforced, and interpreted in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to its
principles of conflict of laws. 

  

									
	Sponsor	 		 	Principal Investigator
			
	/s/ Manish Singh	 		 	/s/ Bruce Levine
					
	Date:	 	Jan. 3, 2011	 		 	By	 	December 23, 2010

  
 15Placement Agent Agreement - Gilford

 EXHIBIT 10.50 

 

 

 March 30, 2010 
 Dr. Manish Singh, CEO 
 ImmunoCellular Therapeutics, Ltd. 

21900 Burbank Boulevard 
 Woodland Hills, CA
91367 
 Dear Dr. Singh: 
 The purpose of this agreement (the “Agreement”) is to set forth the terms and conditions pursuant to which Gilford Securities, Inc. (“Gilford”) shall act as advisor and placement agent
for ImmunoCellular Therapeutics, Ltd. (the “Company”). Gilford shall act on a non-exclusive basis as an advisor and placement agent for introducing the Company to institutional healthcare-focused investors, potential strategic
investors/partners/acquirors and other potential investors in connection with a proposed placement (the “Private Placement”) of equity securities (the “Securities”) of the Company, potential partnering transactions, potential
strategic investments and potential merger and acquisition opportunities. The gross proceeds from the Private Placement are proposed to be up to $15 Million. The terms of such “best efforts” Private Placement, including the identified use
of proceeds, closing conditions and the Securities to be issued shall be agreed to by the Company in its sole discretion. The term of this engagement, unless extended by the Company and Gilford in writing, shall be six (6) months from the date
of this Agreement. 
 The parties hereto hereby agree that the Company shall pay to Gilford the fees and compensation set forth
below if there is any closing and funding of an equity financing, (including without limitation the Private Placement) for the Company (a “Financing”), a partnering transaction or a merger or acquisition transaction within eighteen
(18) months of the date of this Agreement with any investors or strategic investors/partners/acquirors to whom the Company was introduced by Gilford or who was contacted by Gilford and who in each such case was identified in advance by Gilford
to the Company and as to who the Company agrees in writing have been introduced by Gilford for the Private Placement or for a strategic transaction or merger or acquisition (“Investors”), regardless of whether this Agreement was previously
terminated. 
 In consideration of the services rendered by Gilford under this Agreement, the Company agrees to pay Gilford the
following fees and other compensation with respect to Financing amounts and proceeds from strategic transactions, mergers and acquisitions provided by Investors: 

					
	IMMUNOCELLULAR THERAPEUTICS, LTD.	  	 	MARCH 30, 2010	  

 (a) a
cash fee payable immediately upon the closing and funding of any placement of preferred stock, common stock, convertible debt or convertible preferred stock, or any other form of common stock-linked security equal to [7.0%] of the gross
proceeds of such transaction plus warrants to purchase a number of shares of common stock of the Company equal to [7.0%] of the common shares or common share equivalents issued in any such financing at an exercise price equal to the
Company’s then current stock price; 
 (b) a cash fee equal to 5% of the aggregate transaction value on any acquisition of
the Company; 
 (c) a cash fee equal to 5% of the gross proceeds to the Company from any partnering transaction, including all
up-front payments, milestones and any other pre-commercialization payments to the Company made in conjunction with such partnership other than research and development funding payments, as, when and if received by the Company; 

(d) reimbursement of all direct out-of-pocket expenses on a monthly basis, such expenses not to exceed an aggregate of $4,000 without the
written acceptance of the Company; and 
 (e) all amounts payable hereunder, with the exception of the reimbursement of
out-of-pocket expenses, shall be paid to Gilford out of an attorney escrow account at the closing or by such other means acceptable to Gilford. 
 The Company may apply the $10,000 retainer paid to Gilford pursuant to the October 13, 2009 engagement agreement between the parties to any fees payable to Gilford under this Agreement upon the
closing of any Financing. 
 Gilford represents and warrants to, and covenants with, the Company as follows: 

(a) None of Gilford, its affiliates or any person acting on behalf of Gilford or any of such affiliates has engaged or will engage in any
general solicitation. 
 (b) Gilford will use its best efforts to conduct the offering and sale of Securities so that Securities
are sold in a transaction or series of transactions exempt from registration under the Securities Act. 
 (c) Gilford will send
materials related to the Financings only to persons that Gilford reasonably believes are “accredited investors” (as defined under Rule 501(a) of the Securities Act). 
 (d) Gilford agrees that, except as otherwise required by law, regulation or court order or as contemplated by its engagement hereunder, the non-public Information furnished to Gilford by the Company shall
be held by Gilford as confidential. 
 (e) Gilford is registered with FINRA and holds all federal and state licenses or
registrations required to conduct its activities as contemplated by this Agreement. 

  
 2 of 5

					
	IMMUNOCELLULAR THERAPEUTICS, LTD.	  	 	MARCH 30, 2010	  

  

 This Agreement shall be governed by and construed in accordance with the laws of the
State of New York, without regard to conflicts of law principles. 
 The Company and Gilford hereby agree to the terms and
conditions of the Indemnification Agreement attached hereto as Appendix A with the same force and effect as if such terms and conditions were set forth at length herein. 
 This Agreement constitutes the entire understanding and agreement between the parties hereto with respect to its subject matter and there are no agreements or understanding with respect to the subject
matter hereof which are not contained in this Agreement. This Agreement may be modified only in writing signed by the party to be charged hereunder. 
 If the foregoing correctly sets forth our agreement, please confirm this by signing and returning to us the duplicate copy of this letter. 

 

			
	Very truly yours,
	
	GILFORD SECURITIES, INC.
		
	By:	 	/s/ Robert Maley
		 	Robert Maley, President
	
	Date: 4/5/2010

  

			
	ACCEPTED AND AGREED TO:
	
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	By:	 	/s/ Manish Singh
		 	Dr. Manish Singh, CEO
	
	Date: 4/12/2010

  
 3 of 5

					
	IMMUNOCELLULAR THERAPEUTICS, LTD.	  	 	MARCH 30, 2010	  

  

 APPENDIX A 

INDEMNIFICATION AGREEMENT 
 Appendix A to Letter Engagement Agreement (the “Agreement”), dated March 30, 2010 by and between ImmunoCellular Therapeutics, Ltd. (the “Company”) and Gilford Securities, Inc.
(“Gilford”). 
 The Company agrees to indemnify and hold Gilford and its affiliates, control persons, directors,
officers, employees and agents (each an “Indemnified Person”) harmless from and against all losses, claims, damages, liabilities, costs or expenses, including those resulting from any threatened or pending investigation, action, proceeding
or dispute whether or not Gilford or any such other Indemnified Person is a party to such investigation, action, proceeding or dispute, arising out of Gilford’s entering into or performing services under this Agreement, or arising out of any
matter referred to in this Agreement. This indemnity shall also include Gilford’s and/or any such other Indemnified Person’s reasonable attorneys’ and accountants’ fees and out-of-pocket expenses incurred in such investigations,
actions, proceedings or disputes which fees, expenses and costs shall be periodically reimbursed to Gilford and/or to any such other Indemnified Person by the Company as they are incurred; provided, however, that the indemnity herein set forth shall
not apply to an Indemnified Person where a court of competent jurisdiction has made a final determination that such Indemnified Person acted in a grossly negligent manner or engaged in willful misconduct in the performance of the services hereunder
which gave rise to the loss, claim, damage, liability, cost or expense sought to be recovered hereunder (but pending any such final determination the indemnification and reimbursement provisions hereinabove set forth shall apply and the Company
shall perform its obligations hereunder to reimburse Gilford and/or each such other Indemnified Person periodically for its, his or their fees, expenses and costs as they are incurred). The Company also agrees that no Indemnified Person shall have
any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with any act or omission to act as a result of its engagement under this Agreement except for any such liability for losses, claims,
damages, liabilities or expenses incurred by the Company that is found in a final determination by a court of competent jurisdiction to have resulted from such Indemnified Person’s breach of this Agreement or gross negligence or willful
misconduct. 
 If any action, suit, proceeding or investigation is commenced, as to which Gilford proposes to demand
indemnification, it shall promptly notify Company in writing and Company shall have the right to assume the defense of such action. If Company assumes the defense, an Indemnified Person shall have the right to retain counsel of it own choice to
represent it; however, the fees, expenses and disbursements of such counsel shall be borne by the Indemnified Person. It is also understood and agreed that if Company does not elect to assume such defense, Company shall not, in connection with any
one such action or separate substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one counsel for Gilford and all
other Indemnified Persons combined, which counsel shall be mutually agreed upon by Company and Gilford. 

  
 4 of 5

					
	IMMUNOCELLULAR THERAPEUTICS, LTD.	  	 	MARCH 30, 2010	  

  

 If for any reason, the foregoing indemnification is unavailable to Gilford or any such
other Indemnified Person or insufficient to hold it harmless, then the Company shall contribute to the amount paid or payable by Gilford or any such other Indemnified Person as a result of such loss, claim, damage or liability in such proportion as
is appropriate to reflect not only the relative benefits received by the Company and its shareholders on the one hand and Gilford or any such other Indemnified Person on the other hand, but also the relative fault of the Company and Gilford or any
such other Indemnified Person, as well as any relevant equitable considerations; provided that in no event will the aggregate contribution by Gilford and any such other Indemnified Person hereunder exceed the amount of fees actually received by
Gilford pursuant to this Agreement. The reimbursement, indemnity and contribution obligations of the Company hereinabove set forth shall be in addition to any liability which the Company may otherwise have and these obligations and the other
provisions hereinabove set forth shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Company, Gilford and any other Indemnified Person. 

The terms and conditions hereinabove set forth in this Appendix A shall survive the termination and expiration of this Agreement and
shall continue indefinitely thereafter. 
  

			
	GILFORD SECURITIES, INC.
		
	By:	 	/s/ Robert Maley
		 	Robert Maley, President

  

			
	ACCEPTED AND AGREED TO:
	
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	By:	 	/s/ Manish Singh
		 	Dr. Manish Singh, CEO

  
 5 of 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}]]